Back to Ask the Diabetes Team Ask the Diabetes Team

Recently, my daughter's doctor asked her to begin taking Glucophage [metformin, a pill for Type 2 diabetes]. My daughter is a Type 1 diabetic, diagnosed at age 8, currently age 19, and on the insulin pump. The doctor wants her to lose more weight and thus recommended Glucophage (500 mg twice a day). What is the history of Glucophage use with type 1 diabetics this young? Are there any long-term advantages or disadvantages?


Officially Glucophage is not recommended for type 1 insulin dependent diabetics. If there is no family history of type 2 diabetes in your family, then the excessive weight gain may be secondary to overaggressive insulin therapy and may be best treated by cutting back on food and insulin. If there is a strong family history of obesity or type 2 diabetes, then your child might have both type 1 diabetes (insulin deficient) and a component of insulin resistance due to the obesity. Theoretically, in this case Glucophage may be of some help, though I am not aware of any studies evaluating this.

You have to be careful with Glucophage if your child is prone to spilling ketones. This can increase the risk of the rare side effect of Glucophage of lactic acidosis.


Original posting 3 Sep 1999
Posted to Medications: Pills for Diabetes


  Back to Ask the Diabetes Team Return to the Top of This Page

Last Updated: Tuesday April 06, 2010 15:09:06
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.